Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Kathan D. Mehta

Oncology | Hematology Oncology | Hematology
Dlp Conemaugh Physician Practices LLC
1450 Scalp Ave, Suite 2100, 
Johnstown, PA 
Accepting New Patients

Experienced in WT1-Related Wilms Tumor Syndromes
Dlp Conemaugh Physician Practices LLC
1450 Scalp Ave, Suite 2100, 
Johnstown, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathan Mehta is an Oncologist and a Hematologist Oncology provider in Johnstown, Pennsylvania. Dr. Mehta is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Oligodendroglioma, Astrocytoma, Thrombectomy, and Percutaneous Coronary Intervention (PCI). Dr. Mehta is currently accepting new patients.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in KS
Hospital Affiliations
Conemaugh Memorial Medical Center
Conemaugh Miners Medical Center
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

DLP CONEMAUGH PHYSICIAN PRACTICES LLC
1450 Scalp Ave, Suite 2100, Johnstown, PA 15904
Call: 814-269-5211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: ADXS-503, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

57 Total Publications

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2024
View All 57 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology

University Of Pittsburgh Physicians

5115 Centre Ave, 
Pittsburgh, PA 
 (58.4 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shifeng S. Mao
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shifeng S. Mao
Hematology Oncology | Oncology

Allegheny Clinic Medical Oncology

1 Nolte Dr, 
Kittanning, PA 
 (52.3 miles away)
724-543-8657
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shifeng Mao is a Hematologist Oncology specialist and an Oncologist in Kittanning, Pennsylvania. Dr. Mao is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Qamar U. Zaman
Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Qamar U. Zaman
Hematology Oncology
12502 Willowbrook Rd, 
Cumberland, MD 
 (43.7 miles away)
301-777-3111
Languages Spoken:
English, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Qamar Zaman is a Hematologist Oncology provider in Cumberland, Maryland. Dr. Zaman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Anal Cancer, Thrombocytopenia, Non-Hodgkin Lymphoma, Gastric Lymphoma, and Bone Marrow Aspiration. Dr. Zaman is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
      • Advanced
      • Astrocytoma
        Dr. Mehta is
        Advanced
        . Learn about Astrocytoma.
        See more Astrocytoma experts
      • Atypical Teratoid Rhabdoid Tumor (ATRT)
        Dr. Mehta is
        Advanced
        . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
        See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
      • Brain Tumor
        Dr. Mehta is
        Advanced
        . Learn about Brain Tumor.
        See more Brain Tumor experts
      • Embryonal Tumor with Multilayered Rosettes
        Dr. Mehta is
        Advanced
        . Learn about Embryonal Tumor with Multilayered Rosettes.
        See more Embryonal Tumor with Multilayered Rosettes experts
      • Ependymoma
        Dr. Mehta is
        Advanced
        . Learn about Ependymoma.
        See more Ependymoma experts
      • Glioblastoma
        Dr. Mehta is
        Advanced
        . Learn about Glioblastoma.
        See more Glioblastoma experts
      View All 15 Advanced Conditions
      • Experienced
      • Acute Mountain Sickness
        Dr. Mehta is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Adult Immune Thrombocytopenia
        Dr. Mehta is
        Experienced
        . Learn about Adult Immune Thrombocytopenia.
        See more Adult Immune Thrombocytopenia experts
      • Adult Soft Tissue Sarcoma
        Dr. Mehta is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Mehta is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Anemia
        Dr. Mehta is
        Experienced
        . Learn about Anemia.
        See more Anemia experts
      • Angioplasty
        Dr. Mehta is
        Experienced
        . Learn about Angioplasty.
        See more Angioplasty experts
      View All 77 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved